S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Freshworks gets juiced on its AI customer engagement platform
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Freshworks gets juiced on its AI customer engagement platform
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Freshworks gets juiced on its AI customer engagement platform
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Freshworks gets juiced on its AI customer engagement platform

Life Science REIT (LABS) Share Price, News & Analysis

GBX 59.80
-2.40 (-3.86%)
(As of 12/8/2023 ET)
Today's Range
59.60
▼
62.60
50-Day Range
59.80
▼
72.40
52-Week Range
58
▼
77.40
Volume
656,385 shs
Average Volume
746,248 shs
Market Capitalization
£209.30 million
P/E Ratio
N/A
Dividend Yield
6.69%
Price Target
GBX 114
Stock AnalysisAnalyst ForecastsChartDividend

LABS Stock Price History

LABS Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com
Receive LABS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Life Science REIT and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 10/31 Dividend
9/28/2023
Dividend Payable
10/31/2023
Today
12/10/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
LON
Industry
N/A
Sub-Industry
N/A
Sector
N/A
Current Symbol
LON:LABS
CUSIP
N/A
CIK
N/A
Web
www.lifesciencereit.co.uk
Phone
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
GBX 114
High Stock Price Target
GBX 114
Low Stock Price Target
GBX 114
Potential Upside/Downside
+90.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
GBX (0.08)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
£-29,190,000.00
Net Margins
-151.24%
Pretax Margin
N/A
Return on Equity
-8.24%
Return on Assets
0.82%

Debt

Debt-to-Equity Ratio
31.91
Current Ratio
1.35
Quick Ratio
N/A

Sales & Book Value

Annual Sales
£19.30 million
Price / Sales
10.84
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
GBX 90 per share
Price / Book
0.66

Miscellaneous

Outstanding Shares
350,000,000
Free Float
N/A
Market Cap
£209.30 million
Optionable
Not Optionable
Beta
N/A
20 Stocks to Sell Now Cover
20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Sally Ann Forsyth O.B.E.
    Ph.D., Independent Non-Exec. Director & Sustainability Lead
  • Mr. Simon Farnsworth (Age 56)
    Managing Director of Ironstone Asset Management Limited
  • Mr. David Lewis
    Director of Operations & Fin. of Ironstone Asset Management Limited
  • Ms. Joanna Waddingham
    Head of Investor Relations & Corp. Affairs of Ironstone Asset Management Limited
  • Ms. Stephanie Adams
    Legal Counsel of Ironstone Asset Management Limited
  • Mr. Ian Harris
    Director of Asset Management of Ironstone Asset Management Limited
  • Ms. Pippa Stacey
    Head of ESG & Consultant of Ironstone Asset Management Limited
  • Tamara Deering
    Head of Financial Planning & Reporting of Ironstone Asset Management Limited
  • Mr. Daniel Williams
    Corp. & Devel. Financial Controller - Ironstone Asset Management Limited














LABS Stock Analysis - Frequently Asked Questions

Should I buy or sell Life Science REIT stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Life Science REIT in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" LABS shares.
View LABS analyst ratings or view top-rated stocks.

What is Life Science REIT's stock price target for 2024?

1 equities research analysts have issued twelve-month target prices for Life Science REIT's shares. Their LABS share price targets range from GBX 114 to GBX 114. On average, they predict the company's stock price to reach GBX 114 in the next twelve months. This suggests a possible upside of 90.6% from the stock's current price.
View analysts price targets for LABS or view top-rated stocks among Wall Street analysts.

How have LABS shares performed in 2023?

Life Science REIT's stock was trading at GBX 72.30 at the start of the year. Since then, LABS stock has decreased by 17.3% and is now trading at GBX 59.80.
View the best growth stocks for 2023 here.

How often does Life Science REIT pay dividends? What is the dividend yield for Life Science REIT?

Life Science REIT declared a dividend on Thursday, September 21st. Shareholders of record on Thursday, September 28th will be paid a dividend of GBX 1 per share on Tuesday, October 31st. This represents a yield of 1.39%. The ex-dividend date is Thursday, September 28th. The official announcement can be accessed at this link.
Read our dividend analysis for LABS.

Is Life Science REIT a good dividend stock?

Life Science REIT (LON:LABS) pays an annual dividend of GBX 4 per share and currently has a dividend yield of 5.95%. LABS has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer.
Read our dividend analysis for LABS.

How do I buy shares of Life Science REIT?

Shares of LABS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:LABS) was last updated on 12/10/2023 by MarketBeat.com Staff

My Account -